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Abstract:  
 
Two new xanthone-anthraquinone heterodimers, acremoxanthone C (5) and acremoxanthone D 
(2), have been isolated from an extract of an unidentified fungus of the Order Hypocreales (MSX 
17022) by bioactivity-directed fractionation as part of a search for anticancer leads from 
filamentous fungi. Two known related compounds, acremonidin A (4) and acremonidin C (3) 
were also isolated, as was a known benzophenone, moniliphenone (1). The structures of these 
isolates were determined via extensive use of spectroscopic and spectrometric tools in 
conjunction with comparisons to the literature. All compounds (1–5) were evaluated against a 
suite of biological assays, including those for cytotoxicity, inhibition of the 20S proteasome, 
mitochondria transmembrane potential, and NF-κB. 
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 Article:
 
INTRODUCTION 
 
Fungi have been a valuable source for drug leads.1,2 As just one contemporary example that 
originated in the Journal of Antibiotics, the fungal metabolite, myriocin, initially called ISP-1 by 
Fujita and colleagues when first isolated from the entomopathogenic fungus Isaria 
sinclairii,3,4 served as a lead-scaffold for the eventual development of fingolimod (FTY720), 
which received approval by the U.S. FDA in 2010 for the treatment of multiple 
sclerosis.5 Despite numerous other drug leads from fungi, such as the often cited penicillin, it has 
been postulated that fewer than 10% of the approximately 1.5M fungi in the world have been 
investigated taxonomically.6 As part of a larger program to examine diverse natural product 
source materials, our team has been exploring solid phase cultures of filamentous fungi from the 
Mycosynthetix library, which has over 55,000 accessions, for new anticancer drug leads.1 In the 
course of this research, culture MSX 17022, which was isolated in April 1984 from leaf litter 
collected from a beech tree community near the Mycosynthetix headquarters in Hillsborough, 
NC, USA, yielded a cytotoxic extract, as evidenced by 93% inhibition of H460 cell growth when 
tested at 20 μg/mL. Bioactivity-directed fractionation led to the isolation of a series of xanthone-
anthraquinone heterodimers, two of which (compounds 2 and 5) were new. All compounds were 
examined against a suite of biological targets, including those for cytotoxicity, inhibition of the 
20S proteasome, NF-κB inhibition assay, and mitochondrial transmembrane potential activity. 
 
 
 
Figure 1. Structure of Compounds (1–5) isolated from fungus MSX 17022. 
 
RESULTS AND DISCUSSION 
 
Major Isolates 
 
Identification of Acremonidin A (4) The numbering of the isolated compounds (1–5) originates 
from their elution order on RP-HPLC (see Experimental). However, the major compounds 
isolated in the course of this study were compounds 4 and 5, and thus, they will be discussed 
first. Compound 4 displayed a molecular formula of C33H26O12 from the HRMS data, indicative 
of an index of hydrogen deficiency (IHD) of 21. From the diode array detector of the HPLC, the 
UV maxima were 285 and 359 nm. The Dictionary of Natural Products (DNP)7 was utilized for 
dereplication, using the molecular formula and the UV maxima (with a range of +/− 10 nm from 
the observed maxima) as search criteria. The NMR data of 4 matched that of the single hit from 
DNP, which was acremonidin A,8 an antibacterial agent isolated from an Acremoniumsp. in 
2003. 
 
Structure Elucidation of Acremoxanthone C (5) The HRMS data of compound 5 yielded a 
molecular formula of C33H26O12, identical to that of 4. In the NMR spectra of 
compounds 4 and 5 (both examined in CDCl3), there was a high degree of similarity in those 
signals attributable to the anthraquinone portion of the molecule (e.g. H-1: δH 5.90 for 4, δH 5.96 
for 5; H-3: δH 6.82 for 4, δH 6.88 for 5; H-5: δH 6.75 for 4, δH 6.79 for 5). However, a key 
difference between the 1H NMR spectra of 4 and 5 was the number of phenolic peaks; 4had six 
phenols while 5 only displayed four (Table 1). This could result from the formation of a 
xanthone in5 via coupling of two of the phenols from Rings E and F, with a resultant loss of 
water, as has been reported in the acremoxanthones.9 However, the formula for 5 did not allow 
for loss of water as compared to 4. The13C NMR spectrum of 5 showed 33 resonances (Table 1), 
in agreement with the formula, 19 of which were quaternary, as opposed to 20 quaternary signals 
with 4. Moreover, the UV spectrum showed maxima at 274 and 369 nm, significantly different 
from that of 4. 
 
Another ring-closing possibility, which had been reported previously, was via attack of one of 
the ring E phenols on the aromatic carbon bearing the methyl ester, as in the 
xanthoquinodins.10 2D-NMR data confirmed this type of ring-closure, and in this case, the 
linkage was through O-14. One new non-aromatic proton at δH 5.30 (H-3) and two new non-
aromatic carbons at δC 74.8 (C-3) and 84.9 (C-2) were present in the NMR spectra of 5 as 
compared to 4. The signals for δH 5.30 (H-3) and δC 74.8 (C-3) correlated in the multiplicity-
edited HSQC experiment, indicative of an aliphatic secondary hydroxyl group; this new H-3 
signal correlated to H-4 and H-5 in the COSY spectrum as well. The δH 6.50 signal (H-4) 
correlated to the new quaternary carbon δC 84.9 (C-2) in the HMBC spectrum, while the H-5 
signal (δH 6.13) correlated to the C-3 (δC 74.8) signal. The δH 6.50 resonance (H-4) also 
correlated to δC 171.2 resonance (C-6) in the HMBC spectrum, which was farther downfield than 
a typical phenol carbon, consistent with the enhanced keto character of C-6 resulting from 
tautomerization with the C-8 ketone. These data confirm the proposed E-G-F ring system. The 
relative stereochemistry of C-2 was confirmed by a 1D nOe Difference spectrum, which showed 
an enhancement of H-3 upon irradiation of the H3-16 methyl ester signal. The relative 
stereochemistry of C-1′, C-14′, and C-11′ was established by the ROESY spectrum. The acetate 
methyl group at C-18′ showed a clear ROESY correlation to H-13′, which established the 
relative stereochemistry for the anthraquinone portion of the molecule. Compound 5 therefore 
contained the anthraquinone portion of the acremonidins and acremoxanthones,8,9 and the 
xanthone portion of the xanthoquinodins.10 This compound was named acremoxanthone C to 
maintain consistency with the existing acremoxanthones. 
 
 
 
Table 1. NMR Data for Compounds 2 and 5 (2 in DMSO-d6, 5 in CDCl3, 500 MHz, chemical 
shifts in δ, coupling constants in Hz). 
Minor Isolates 
 
Identification of Moniliphenone (1) According to HRMS data, compound 1 had the formula 
C16H14O6. The1H NMR showed singlets due to aromatic methyl and methoxy groups. Aromatic 
region signals at δH 7.12 (doublet), 7.28 (triplet), and 7.47 (doublet), all with a coupling constant 
of 7.6 Hz, were consistent with a 1,2,3-trisubstituted benzene moiety. Using the 
AntiMarin11 database for dereplication, the formula was entered into the search query, as was 
one 1,2,3-trisubstituted benzene and one methoxyl. Only two hits resulted from this query; 
moniliphenone and nidulalin B12 both of which had 1H-NMR data that were consistent with the 
spectra of 1. However, the HMBC spectra revealed a key correlation between the δH 7.47 doublet 
and the δC 166.0 signal (ester carbonyl), establishing moniliphenone as the structure of 1; the 1H- 
and 13C-NMR data matched the literature.13 
 
Structure Elucidation of Acremoxanthone D (2) The HRMS data of compound 2 indicated a 
formula of C33H26O13, establishing an IHD of 21. The NMR data for compounds 2 and 5 were 
quite similar. The formula indicates the addition of one oxygen, similar to the difference of one 
oxygen between acremonidin A (4) and acremonidin C (3). Initially, it was expected that the 
extra oxygen of 2 would present as a hydroxy group at position C-9′, as was noted with 
acremonidin C (3).8 However, the HMBC spectrum did not confirm this. The oxygen instead was 
shown to be added as a hydroxy group at position C-7. Indeed, the C-7 resonance in the 13C-
NMR spectrum of 2 was at δC 79.1, as opposed to δC 99.2 with 5. Correspondingly, a new singlet 
appeared in the 1H NMR spectrum of 2 at δH 8.13, with no HSQC correlation, indicating a 
hydroxy or phenol proton. This -OH proton correlated in the HMBC to the C-2 signal at δC 90.6, 
identifying the -OH as hydroxy. The carbon resonance for C-6 was farther downfield at δC 188.2 
(vs. 171.2 for 5), indicating more keto character due to the lack of tautomerization with C-8. The 
relative stereochemistry for 2was established from the ROESY spectrum. The key observation 
was a strong correlation between the 7-OH proton and H-3. Of the four possible diastereomeric 
combinations of C-2 and C-7, only one possibility allows close approach of the 7-OH and H-3 
according to Chem3D energy minimization, and that is with the C-2 methyl ester in the β 
position and the C-7 hydroxy in the α position. Due to the similarities between 
compounds 2 and 5, compound 2 was ascribed the trivial name, acremoxanthone D. 
 
Identification of Acremonidin C (3) The HRMS of compound 3 indicated a formula of 
C33H26O13, identical to the formula for 2, however, the NMR spectra showed significant 
differences. From the diode array detector of the HPLC, the UV maxima were 275 and 341 nm, 
also differing significantly from 2 (287 and 362 nm). The Dictionary of Natural Products 
(DNP)7 was again used for dereplication with molecular formula and UV maxima (with a range 
of +/− 10 nm from the observed maxima) as search criteria. A single hit was identified in DNP, 
and the NMR data of 3 matched that of acremonidin C.8 
 
Conversion of Compound 5 to 4 To determine the absolute configuration of compound 5, an 
attempt was made to synthesize the Mosher esters from the MTP chlorides in 
pyridine.14 However, when the reaction was attempted, compound 4 was by far the major 
product, with numerous very minor products. When compound 5 was treated with pyridine only, 
the result was nearly complete conversion to 4 after 4.5 h at room temperature. This would 
indicate that H-3 of compound 5 is susceptible to basic attack followed by opening of the G-ring 
to yield 4 (Figure 2). This may not have been an issue with the xanthoquinodins (which also 
contain the E-G-F ring system), most likely because those compounds have a single bond 
between C-4 and C-5. The driving force behind the conversion of 5 to 4 may be the creation of 
aromaticity, which can’t occur with the xanthoquinodins. Therefore, absolute configurations 
were not determined for either 2 or 5. 
 
 
 
Figure 2. Proposed conversion of compound 5 to 4 by pyridine at room temperature. 
 
Biological Activity Compounds 1–5 were assayed against three cancer cell lines and showed 
moderate cytotoxic activity in vitro, with IC50 values summarized in Table 2. Compounds 2, 3, 
and 4 showed moderate 20S proteasome inhibitory activity as well (Table 2). All compounds 
were inactive in assays for both NF-κB inhibition and mitochondrial transmembrane potential 
(i.e. IC50 values > 20 μM; data not shown). 
 
CONCLUSION 
 
Using bioactivity-directed fractionation, five compounds were isolated from an extract of MSX 
17022, an unidentified fungus of the Order Hypocreales. Two of these compounds (2 and 5) 
were found to be new xanthone-anthraquinone heterodimers. The biological activity of these five 
compounds was found to be moderate for cytotoxicity and 20S proteasome inhibitory activity 
(Table 2). Regardless, the biosynthetic potential of this fungus was quite intriguing, particularly 
the generation of xanthone-anthraquinone heterodimers. Even a non-optimized culture, first 
isolated nearly three decades ago, produced structurally diverse compounds on the scale of 
hundreds of mg per 2.8 L culture. 
 
 
 
Table 2. Cytotoxicity Against a Panel of Human Tumor Cell Lines and Inhibition of 20S 
Proteasome of Compounds Isolated from MSX 17022 (1–5). 
 
EXPERIMENTAL SECTION 
 
General 
 
Optical rotations, UV spectra, and IR spectra were obtained on a Rudolph Research Autopol III 
polarimeter, a Varian Cary 100 Bio UV-vis spectrophotometer, and a Perkin-Elmer Spectrum 
One with Universal ATR attachment, respectively. NMR experiments were conducted in either 
DMSO-d6 or CDCl3 with TMS as reference using a JEOL ECA-500 (operating at 500 MHz 
for 1H, 125 MHz for 13C). HRESIMS were performed on a Waters SYNAPT MS system using a 
capillary voltage of 2000 V (positive mode) and 1000 V (negative mode); sampling cone 
voltages were 40 V (positive mode) and 10 V (negative mode). Flash chromatography was 
conducted using a CombiFlash Rf system using a RediSep Rf Si-gel Gold column (both from 
Teledyne-Isco; Lincoln, NE, USA). HPLC was carried out on Varian Prostar HPLC systems 
(Walnut Creek, CA, USA) equipped with Prostar 210 pumps and a Prostar 335 photodiode array 
detector (PDA), with data collected and analyzed using Galaxie Chromatography Workstation 
software (version 1.9.3.2). For preparative HPLC, a Gemini-NX (5 μm; 250 × 21.2 mm) column 
was used with a 15 mL/min flow rate, while for analytical HPLC, a Gemini-NX (5 μm; 150 × 4.6 
mm) column was used with a 1 mL/min flow rate (both from Phenomenex; Torrance, CA, USA). 
 
Producing Organism and Fermentation 
 
Mycosynthetix fungal strain 17022 was isolated by Dr. Barry Katz of MYCOsearch in April of 
1984 from leaf litter from a beech tree community in Hillsborough, NC, USA. DNA analyses 
were performed by MIDI Labs, Inc. (Newark, DE), and the D2 variable region of the Large 
Subunit (LSU) rRNA was sequenced and compared to their database. This analysis suggested 
that this fungus was of the Order Hypocreales; these data were deposited in Genbank (accession 
No. JN185925). The culture was stored on a malt extract slant and was transferred periodically. 
A fresh culture was grown on a similar slant, and a piece was transferred to a medium containing 
2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). Following incubation (7 d) 
at 22 °C with agitation, the culture was used to inoculate 50 mL of a rice medium, prepared 
using rice to which was added a vitamin solution and twice the volume of rice with H2O, in a 250 
mL Erlenmeyer flask. This was incubated at 22°C until the culture showed good growth 
(approximately 14 d). The scale up culture was grown in a 2.8 L Fernbach flask containing 150 g 
rice and 300 mL H2O and was inoculated using a seed culture grown in YESD medium. This was 
incubated at 22°C for 14 d. 
 
Extraction and Isolation 
 
To the scale-up solid fermentation on rice were added 500 mL of 1:1 MeOH-CHCl3, and the 
mixture was shaken for 16 h on a reciprocating shaker. The solution was filtered and equal 
volumes of H2O and CHCl3were added to the filtrate to bring the total volume to 2 L. The 
solution was stirred vigorously for 1 h, partitioned in a separatory funnel, and the bottom, 
organic layer was concentrated by rotary evaporation to dryness. This extract was stirred 
vigorously for 1 h in a mixture of 150 mL MeOH, 150 mL CH3CN, and 200 mL hexane and then 
partitioned in a separatory funnel. The bottom layer was collected and evaporated to dryness 
(5.93 g). This defatted extract was adsorbed onto a minimal amount of Celite 545 and dried with 
mixing via a mortar and pestle. This material was fractionated at 40 mL/min on a RediSep Rf 
Gold silica gel column (40 g), first with 100% hexanes for 0.7 column volumes (CV) followed 
by a gradient of 100% hexanes to 100% CHCl3 over 8.9 CV. The elution continued with 100% 
CHCl3 for 7.4 CV, then with a gradient of MeOH in CHCl3 (0–2% over 9.7 CV, then 2–5% over 
5.2 CV, then 5–10% over 5.2 CV, then 10–20% over 3.7 CV, then 20–100% over 2.2 CV. 
MeOH (100%) was finally held for a further 6.7 CV). Fractions were collected every 24.75 mL. 
Compounds 1–4 were present in fractions 56–67, which were combined and evaporated (688.9 
mg). Compound 5 was present in fractions 22–39 (370.9 mg). The combined fraction 56–67 was 
then subjected to preparative HPLC in three injections, 40–100% CH3CN in H2O over 30 min. 
Fractions were collected every 0.5 min. Elution times and amounts isolated were: 1; 15–15.5 min 
(16.8 mg), 2; 19.5–20 min (8.4 mg), 3; 21–21.5 min (16.1 mg), 4; 21.5–23.5 min (337.7 mg). 
The combined fraction 22–39 was purified by preparative HPLC using the identical conditions as 
above (in two injections), and compound 5 was collected between 26–28 min (327.5 mg). 
 
Acremoxanthone C (5) 
 
Compound 5 was isolated as a yellow solid (327.5 mg); [α]D23 +576 (c 0.33, MeOH); UV 
(MeOH) λmax(log ε), 273 (4.03), 371 (4.43) nm; IR (diamond) νmax 2956, 1736, 1634, 1566, 
1469, 1368, 1219, 1097, 871, 711 cm−1; 1H NMR (CDCl3, 500 MHz), and 13C NMR (CDCl3, 125 
MHz), see Table 1. HRMS m/z637.1331 [M + Na]+; 613.1340 [M - H] − (calcd for C33H26O12Na, 
637.1322; calcd for C33H25O12, 613.1346). 
 
Acremoxanthone D (2) 
 
Compound 2 was isolated as a yellow solid (8.4 mg); [α]D23 +235 (c 0.33, MeOH); UV 
(MeOH) λmax (log ε), 287 (4.07), 362 (4.17) nm; IR (diamond) νmax 3055, 1731, 1702, 1609, 
1566, 1355, 1278, 1219, 1020, 818 cm−1; 1H NMR (DMSO-d6, 700 MHz), and 13C NMR 
(DMSO-d6, 175 MHz), see Table 1. HRMSm/z 653.1277 [M + Na]+; 629.1294 [M - H] − (calcd 
for C33H26O13Na, 653.1271; calcd for C33H25O13, 629.1295). 
 
Conversion of 5 to 4 
 
Compound 5 was stirred in pyridine at room temperature. The progress of the conversion 
of 5 to 4 was monitored by analytical RP-HPLC at 1 h, 2 h, 3 h, and 4.5 h. 
 
Cytotoxicity Assay 
The cytotoxicity measurements against the MCF-715 human breast carcinoma (Barbara A. 
Karmanos Cancer Center), NCI-H46016 human large cell lung carcinoma (HTB-177, American 
Type Culture Collection (ATCC), SF-26817 human astrocytoma (NCI Developmental 
Therapeutics Program), HT-2918 human colorectal adenocarcinoma (HTB-38, ATCC) and the 
MDA-MB-43519 human melanoma (HTB-129, ATCC) cell lines were performed exactly as 
described in detail previously.20 
 
20S Proteasome Assay 
 
Human mammary adenocarcinoma cells15 (MCF-7; American Type Culture Collection, 
Manassas, VA) were propagated at 37°C in 5% CO2 in RPMI 1640 medium supplemented with 
fetal bovine serum (10%) with penicillin (100 units/mL) and streptomycin (100 μg/mL). Cells in 
log phase growth were harvested by trypsinization followed by extensive washing to remove all 
traces of enzyme. A total of 7,500 cells were seeded per well of a 96-well microtiter plate and 
incubated overnight (37°C in 5% CO2). Samples dissolved in DMSO were then added to achieve 
the final concentrations as indicated (total volume: 100 μL; DMSO: 0.2%). The cells were 
incubated in the presence of test substance for 2 h at 37°C and evaluated for proteasome activity 
using a commercial luminescent assay (Proteasome-Glo™, Promega Corp, Madison, WI) that 
measures the chymotrypsin-like, trypsin-like or caspaselike protease activity associated with the 
proteasome complex. Activity was expressed as percent inhibition relative to negative (solvent) 
control. The positive control was bortezomib tested at 5 nM and 25 nM, which inhibited 
proteasome activity by 27% and 91% respectively. 
 
NF-κB Assay 
 
An ELISA based NF-κB inhibitory assay was performed exactly as described 
previously.20 Rocaglamide (Enzo Life Sciences International, Inc.) was used as a positive control 
(IC50 value of 0.075 μM). 
 
Mitochondrial Transmembrane Potential (ΔΨ) Assay 
 
The mitochondrial transmembrane potential assay kit (Cayman Chemical Company, Ann Arbor, 
MI) was adapted to detect the ΔΨ using a procedure published previously.21 ΔΨ is used to 
represent mitochondrial membrane transition events. The specific details were outlined 
recently,20 and staurosporine (Cayman) was used as a positive control (IC50 value of 2.5 nM). 
 
SUPPLEMENTARY MATERIAL 
 
 
 
Figure S1. 1H NMR Spectrum of Acremoxanthone D (2) in DMSO-d6, 500 MHz 
 
 
 
Figure S2. 13C NMR Spectrum of Acremoxanthone D (2) in DMSO-d6, 125 MHz 
 
 
 
Figure S3. 1H NMR Spectrum of Acremoxanthone C (5) in CDCl3, 500 MHz 
 
 
 
Figure S4. 13C NMR Spectrum of Acremoxanthone C (5) in CDCl3, 125 MHz 
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FOOTNOTES 
 
1H and 13C NMR spectra for compounds 2 and 5. This information is available via the internet. 
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